Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global In Vitro Diagnostics Market to Reach USD 157.63 Billion by 2030 | MarketsandMarkets™

globenewswire.com
ILMN Mentioned as a prominent player in the competitive IVD landscape, driving innovation through R&D and global expansions. No specific positive or negative performance indicated. HOLX Listed as a prominent player in the IVD market, contributing to the competitive landscape and innovation through R&D and global expansions. No specific sentiment is attached. BIO Identified as a prominent player in the IVD market, contributing to innovation and market competition through R&D and expansions. No specific positive or negative performance is detailed. BDX Identified as a prominent player in the IVD market, contributing to innovation and competition. The article does not specify sentiment regarding its performance. AGNC Named as a prominent player in the IVD market, involved in innovation and global expansion. The article does not provide specific sentiment regarding its performance. QGEN Mentioned as a prominent player in the IVD market, contributing to innovation and competition. The article does not offer specific sentiment about the company's performance. GRFS Identified as a prominent player in the IVD market, contributing to innovation and competition. The article does not specify sentiment regarding its performance.

Global In Vitro Diagnostics Market to Reach USD 157.63 Billion by 2030 | MarketsandMarkets™ Delray Beach, FL , March 12, 2026 (GLOBE NEWSWIRE) -- The global in vitro diagnostics (IVD) market, valued at USD 101.05 billion in 2024, has advanced to USD 109.06 billion in 2025 and is projected to grow at a resilient compound annual growth rate (CAGR) of 7.6% through 2030, reaching USD 157.63 billion by the end of the forecast period. This substantial expansion reflects fundamental shifts in healthcare delivery priorities, diagnostic technology capabilities, and global investment patterns that are reshaping clinical operations and strategic planning across hospitals, laboratories, and diagnostic service providers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703

Why the Market is Expanding and How It Impacts Strategy

The momentum driving the IVD landscape is fundamentally fueled by an escalating global burden of chronic and infectious diseases, coupled with a surging clinical demand for early, high-precision detection. In emerging economies, heightened awareness and government-backed screening programs are rapidly unlocking lucrative new revenue streams. To capitalize on these opportunities, decision-makers must strategically address stringent regulatory roadblocks—such as Europe’s evolving IVDR frameworks and rigorous FDA standards—which continue to inflate compliance costs and extend product development lifecycles.

Where Capital is Flowing: High-Yield Segments and Technologies

Investment priorities are heavily concentrating in segments that guarantee recurring revenue and workflow efficiency. Reagents and kits currently command the largest market share, acting as the indispensable backbone for automated analyzers and clinical chemistry workflows. Technologically, immunoassays lead the sector, propelled by high-sensitivity chemiluminescence and multiplexing platforms that deliver rapid turnaround times for oncology, endocrinology, and infectious disease testing.

Blood, serum, and plasma remain the dominant clinical specimens, reliably anchoring diagnostic workflows across the globe's busiest testing sites: centralized laboratories and hospital networks. Geographically, North America maintains its stronghold, leveraging advanced healthcare infrastructure and heavy precision medicine investments, though emerging markets are aggressively closing the gap.

Overcoming Operational Disruption Despite the highly lucrative outlook, Chief Operating Officers and laboratory directors face tangible operational friction. Shortages of skilled laboratory personnel, supply chain volatility, and high instrument maintenance costs threaten workflow efficiencies. To mitigate these risks, major healthcare institutions—including the Cleveland Clinic and Johns Hopkins Medicine—are increasingly relying on fully automated, high-throughput systems that reduce manual intervention, stabilize testing environments, and standardize clinical decision-making.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=703

Who is Leading the Charge: Strategic Moves by Top Market Players

The competitive landscape is aggressively consolidating, with the top five market leaders driving innovation through strategic M&A, advanced R&D blitzes, and global expansions:

Other prominent players shaping the market ecosystem include Illumina, Inc., Hologic, Inc., Bio-Rad Laboratories, bioMérieux, Sysmex Corporation, Revvity Inc, Becton, Dickinson and Company, Agilent Technologies, Qiagen, DiaSorin S.p.A., Grifols, S.A., Werfen, and QuidelOrtho Corporation.

For more information, Inquire Now!

Discover Connected Healthcare Market Opportunities:

Europe IVD Market

APAC IVD Market

US IVD Market

Latin America IVD Market

Middle East and Africa IVD Market

Get access to the latest updates on Top Companies in In Vitro Diagnostics and In Vitro Diagnostics Market Size